Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$27.67 -1.3%	$26.94	$17.38 ▼ $30.69	$2.05B	0.06	549,019 shs	948,384 shs
MRSN Mersana Therapeutics	$0.30 +1.7%	$0.36	$0.26 ▼ $2.83	$36.27M	0.83	2.69 million shs	3.57 million shs
OMER Omeros	$3.00 -6.3%	$4.45	$2.97 ▼ $13.60	$187.50M	2.21	713,388 shs	1.24 million shs
PRAX Praxis Precision Medicines	$42.05 -2.2%	$39.77	$26.70 ▼ $91.83	$875.87M	2.61	367,115 shs	341,828 shs
STOK Stoke Therapeutics	$11.35 -2.4%	$10.22	$5.35 ▼ $16.15	$634.96M	1.09	675,566 shs	509,358 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	0.00%	-1.41%	+2.22%	+26.25%	+50.19%
MRSN Mersana Therapeutics	0.00%	-20.47%	-15.16%	-15.46%	-85.52%
OMER Omeros	0.00%	-0.31%	+2.89%	-61.07%	-21.18%
PRAX Praxis Precision Medicines	0.00%	+1.56%	+11.46%	+13.55%	+3.97%
STOK Stoke Therapeutics	0.00%	+0.43%	+21.02%	+74.89%	-13.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KNSA Kiniksa Pharmaceuticals International	3.3782 of 5 stars	3.5	4.0	0.0	2.1	3.3	0.6
MRSN Mersana Therapeutics	3.9742 of 5 stars	3.5	1.0	4.1	3.3	2.5	0.0
OMER Omeros	3.6569 of 5 stars	3.4	0.0	4.4	2.0	1.7	0.6
PRAX Praxis Precision Medicines	3.2243 of 5 stars	4.4	2.0	0.0	3.7	1.7	0.0
STOK Stoke Therapeutics	3.9905 of 5 stars	3.6	0.0	4.8	2.5	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$38.80	40.22% Upside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,656.76% Upside
OMER Omeros	2.83	Moderate Buy	$18.00	500.00% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$109.90	161.36% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	104.41% Upside

Current Analyst Ratings Breakdown

Latest KNSA, MRSN, STOK, OMER, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/10/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.77	N/A	N/A	$6.60 per share	4.19
MRSN Mersana Therapeutics	$40.50M	0.91	N/A	N/A	($0.08) per share	-3.70
OMER Omeros	N/A	N/A	N/A	N/A	($3.15) per share	N/A
PRAX Praxis Precision Medicines	$8.55M	100.18	N/A	N/A	$23.90 per share	1.76
STOK Stoke Therapeutics	$190.91M	3.25	N/A	N/A	$4.32 per share	2.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	110.68	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
OMER Omeros	-$156.82M	-$2.65	N/A	N/A	N/A	N/A	N/A	-59.68%	8/6/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.37	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)

Latest KNSA, MRSN, STOK, OMER, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/31/2025	Q4 2024	OMER Omeros	-$0.71	-$0.63	+$0.08	-$0.54	$0.40 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
MRSN Mersana Therapeutics	13.35	1.83	1.83
OMER Omeros	N/A	1.16	1.16
PRAX Praxis Precision Medicines	N/A	8.44	8.44
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KNSA Kiniksa Pharmaceuticals International	53.95%
MRSN Mersana Therapeutics	93.92%
OMER Omeros	48.79%
PRAX Praxis Precision Medicines	67.84%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
KNSA Kiniksa Pharmaceuticals International	53.48%
MRSN Mersana Therapeutics	13.00%
OMER Omeros	12.90%
PRAX Praxis Precision Medicines	2.70%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
OMER Omeros	210	58.59 million	51.04 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

KNSA, MRSN, STOK, OMER, and PRAX Headlines

Recent News About These Companies

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Buy" from Analysts

June 30 at 2:29 AM | marketbeat.com

STOK Stoke Therapeutics, Inc. - Seeking Alpha

June 29 at 9:44 AM | seekingalpha.com

Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Legend Biotech (LEGN)

June 28 at 3:13 PM | theglobeandmail.com

Stoke-on-Trent bungalow could be turned into children's home

June 28 at 10:12 AM | msn.com

Stoke City confirm new coach appointment as pre-season starts

June 27 at 7:09 PM | msn.com

Traditional Stoke-on-Trent pub reopens for the first time since Covid

June 27 at 7:09 PM | stokesentinel.co.ukS

Stoke Therapeutics (NASDAQ:STOK) Trading Down 3.5% - Here's Why

June 26, 2025 | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025 | businesswire.com

STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald

June 16, 2025 | marketbeat.com

Stoke Therapeutics: Impressive Pipeline And Big Backers

June 15, 2025 | seekingalpha.com

Assenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 15, 2025 | marketbeat.com

Cantor Fitzgerald Predicts STOK FY2026 Earnings

June 10, 2025 | marketbeat.com

Kangaroo Care Awareness Day celebrated at Stoke Mandeville Hospital

June 10, 2025 | msn.com

Jong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”

June 10, 2025 | sports.yahoo.com

Stoke City confirm next stage of major badge consultation

June 10, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 10, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 8, 2025 | marketbeat.com

Stoke City Secure Youth International Amid Leeds United Interest

June 7, 2025 | therealefl.co.ukT

Business forum will look at how the Stoke-on-Trent and Staffordshire area sells itself to the world

June 7, 2025 | expressandstar.comE

Five hours of 'thundery showers' to rock Stoke-on-Trent today

June 7, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
Broadcom Slides on Solid Earnings, AI Outlook Still Strong
By Leo Miller | June 6, 2025
View Broadcom Slides on Solid Earnings, AI Outlook Still Strong
GE Aerospace Turns Engines Into Long-Term Profits
By Jeffrey Neal Johnson | June 21, 2025
View GE Aerospace Turns Engines Into Long-Term Profits
Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?
By Leo Miller | June 28, 2025
View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?
Red Robin's Comeback: Q1 Earnings Spark Investor Hopes
By Jeffrey Neal Johnson | June 5, 2025
View Red Robin's Comeback: Q1 Earnings Spark Investor Hopes

KNSA, MRSN, STOK, OMER, and PRAX Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$27.67 -0.37 (-1.32%)

As of 04:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Mersana Therapeutics NASDAQ:MRSN

$0.30 +0.01 (+1.72%)

As of 04:00 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Omeros NASDAQ:OMER

$3.00 -0.20 (-6.25%)

As of 04:00 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Praxis Precision Medicines NASDAQ:PRAX

$42.05 -0.95 (-2.21%)

As of 04:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$11.35 -0.28 (-2.41%)

As of 04:00 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time